Best Practices for Contract Research Organizations and Sponsors
The biopharmaceutical industry is increasingly incorporating the voice of the patient in the drug development process, but how effective are these interactions from the perspective of rare disease patients? To explore this question, Covance recently spoke with four leaders who have established their own patient advocacy groups and foundations.
We wanted to hear about their unique experiences – both as people living with rare diseases and trailblazers for patient advocacy – to gather practical recommendations for the drug development industry.
This article focuses on how to strengthen the connections between rare disease communities and a network of stakeholders, specifically examining how to best create mutually beneficial relationships of members of the patient community with contract research organizations (CROs) and Sponsors.
To learn more about Covance , visit their website.